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Abstract
Introduction: This case report describes the effects of psychotropic treatment, quetiapine in particular, on systemic
inflammation, pain, general functioning and major depression in the treatment of a woman with arthritis.
Case presentation: A 49-year-old Caucasian Australian woman with arthritis, pain and depression was treated with
a course of escitalopram, mirtazapine and quetiapine. Pain levels, general functioning and degree of depressive
symptoms were evaluated with a visual analogue scale. Systemic inflammation had been assessed by C-reactive
protein serum levels since 2003. C-reactive protein levels, physical pain, symptoms of arthritis and depression
decreased significantly during the past 12 months of treatment with quetiapine, while treatment with selective
serotonin reuptake inhibitors and mirtazapine remained the same.
Conclusions: We suggest that the treatment particularly with quetiapine may have anti-inflammatory effects in
arthritis and comorbid major depression, which eventually led to a remission of pain and depression and to
normal general function.
Introduction
Patients with major depression often suffer comorbid
physical disorders [1] of which some are related to sys-
temic inflammation, such as cardiovascular disease [2]
and rheumatoid arthritis [3]. In turn, systemic inflam-
mation has been related to the onset and course of
depression [4]. It has been suggested that stress and
inflammatory pathways are involved in the response to
antidepressant treatment [5].
In this case report, we describe a patient with chronic
psoriatic arthritis that cause impairing pain, increased
C-reactive protein levels (CRP) and depressive symp-
toms. However, a significanti m p r o v e m e n to fa r t h r i t i c
symptoms including pain and mental symptoms, as well
as a decrease in CRP, was observed after the patient was
commenced on a combined treatment of psychotropic
medication (antidepressant and atypical neuroleptic).
The treatment subsequently led to a significant increase
in the patient’s levels of general functioning.
Case presentation
A 49-year-old Caucasian Australian woman was referred
by her general practitioner to a specialist clinic for
mood disorders in October 2007 with the request to
assess and manage longstanding symptoms of depres-
sion. Her history shows psoriatic arthritis causing signif-
icant pain since age 43 and mild to moderate depressive
episodes since her early 30 s. In October 2007, the
patient presented with severe emotional disturbance
characterised by anxiety, frustration and depression.
These feelings seemed to be largely brought about by
her decreased mobility as a result of severe, debilitating
arthritic pain in her joints that worsened over the past
12 months prior to assessment. Due to her depression
which had started in 2002, she was seen by her psychia-
trist in the community, who diagnosed her with major
depressive disorder (MDD). * Correspondence: bernhard.baune@jcu.edu.au
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mid-2007, the patient’s arthritic symptom profile had
been progressively worsening. Concomitantly, her
depressive symptoms were worsening over this period of
time due partly to a personal experience of loss (death
of her mother).
When her arthritic disease was worsening between
early 2005 and 2007, she was started on a number of
disease-modifying antirheumatic drugs (DMARDs) and
analgesics (oxycodone, tramadol and paracetamol com-
bined with codeine and taken regularly since 2002) as
prescribed by her rheumatologist (Figure 1). Her intake
of DMARDs was as follows: sulfasalazine (500 mg BID),
hydroxychloroquine (200 mg BD) and leflunomide (20
mg QD) from November 2003 to November 2004; leflu-
nomide (20 mg QD), adalimumab (40 mg once at
night), etanercept (50 mg SC weekly) and infliximab
(300 mg/infusion) from December 2004 to October
2007; and then only leflunomide (20 mg QD) since
October 2007.
Due to a significant aggravation of her depressive
mood, mood instability, po o rs l e e pa n dad e c r e a s ei n
her general functioning, she was treated for MDD with
paroxetine 20 mg/mane in 2002, with risperidone 0.5
mg/bd in 2007, and then with mirtazapine up to 45 mg/
nocte two months before she was assessed for the first
time in a mood disorder clinic in October 2007.
Based on her psychiatric assessment in October 2007,
the previous diagnosis of MDD was confirmed and she
was started on a new course of treatment. While staying
on the same DMARD (leflunomide, 20 mg QD) from
October 2007 onwards, she was commenced on courses
of escitalopram 10 mg/mane (replacing paroxetine), que-
tiapine 50 mg/mane and 100 mg/nocte (replacing risper-
idone, which was previously prescribed to improve
worried thought content), and continued on mirtazapine
30 mg/nocte. She was commenced on quetiapine since
recent evidence suggests the effectiveness of quetiapine
in major depression [6].
In the follow-up consultations in the mood disorder
clinic it became apparent that her depressive symptoms
were continuously improving, and following a month lag
phase her arthritic pain decreased significantly, her
mobility increased, and her CRP levels decreased. This
resulted in a drastically improved depression, which
eventually led to a remission after three months of
treatment.
Between the commencement of the new psychotropic
treatment regimen in October 2007 and the significant
improvement of the depressive symptoms as described
above, the arthritis specific treatment (DMARDs and
analgesics) had not changed. While her CRP levels were
32 mg/L before the start of the new psychotropic treat-
ment regimen, they dropped continuously to 13 mg/L
over 10 months between October 2007 and July 2008
without changing the arthritis specific medication. Due
to the significant decrease in her pain levels, depressive
symptoms and CRP levels, the anti-tumor necrosis fac-
tor treatment (abatcept) discussed previously by her
rheumatologist was no longer considered as a necessary
treatment option. In addition, the patient did not have
any significant lifestyle changes during the same period
of time.
While staying on the above psychotropic medication,
the patient was able to maintain a low level of arthritic
pain throughout the year 2008. Despite some relatively
mild intermittent increase of some of her arthritic pain
and depressive symptoms, which were interpreted as
relatively mild fluctuations over a 12-month period, her
level of general functioning remained high.
Discussion
This case report has a number of interesting findings
that warrant further exploration and discussion. First,
the patient’s depression symptoms were timely and clo-
sely related to physical symptoms such as pain from the
arthritis. Secondly, the combination of selective seroto-
nin reuptake inhibitors (SSRI), antidepressants and que-
tiapine as atypical antipsychotic treatment lifted the
patient’s depression, physical symptoms and CRP levels.
Lastly, her previous treatment with a combination of
drugs of similar classes failed to neither produce rele-
vant relief of either mental and/or physical symptoms
nor lower her CRP levels.
Previous studies found that depression is more com-
mon in arthritis than in healthy subjects [7] and both
disorders are closely related [8]. Depression and arthritis
may be further linked through common inflammatory
pathways, in which cytokines seem to play a major role
[8]. This case report is supports the suggestion that
joint inflammatory pathways between arthritis and
depression as symptoms of arthritis, pain and depression
are simultaneously lifted when CRP levels are lowered.
Although there are some conflicting results, it has
been suggested that antidepressants can lower the levels
of systemic inflammation markers, such as CRP [9] and
cytokines, while also having analgesic effects [10,11]. A
few experiments suggest that paroxetine [12], fluoxetine
and clomipramine [10] also have anti-inflammatory
effects. Extensive research has not been carried out in
this area, thus leaving a lack of data on the potential
anti-inflammatory effects of escitalopram despite a
recent finding that escitalopram lowers the level of solu-
ble interleukin 2 receptor [13]. However, since the
patient was treated with SSRI antidepressants before
(paroxetine) and after (escitalopram), it can be suggested
that the large clinical improvement and reduction in her
CRP was not related to the SSRI treatment alone.
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to be influenced by the effects of mirtazapine as the
patient had been treated continuously with this com-
pound long before and after the clinical improvement.
This leaves us to the discussion of the anti-inflamma-
tory effects of antipsychotic medication on CRP levels
and a patient’s clinical symptoms. The literature shows
less inconsistent findings on the potential anti-inflam-
matory effects of antipsychotics. While some reports
indicate that patients treated with antipsychotics such as
olanzapine exhibit higher levels of inflammatory markers
including CRP [14,15], some early evidence suggests that
clozapine may also decrease inflammatory response as
evinced by a parallel decrease in cytokine expression
[16].
In addition, some atypical antipsychotics such as ris-
peridone are thought to exert a positive effect on the
inflammatory response system in patients with schizo-
phrenia, which possibly accounts for a better treatment
outcome as compared to conventional neuroleptics [17].
More particularly, risperidone has been shown to reduce
pro-inflammatory cytokines such as tumor necrosis fac-
tor alpha and interleukin 6 (IL-6) in mice treated with
lipopolysaccharide (LPS) [18]. In this case report, the
treatment with risperidone failed to show reductions in
CRP level and relevant symptoms of arthritis, pain and
depression. In contrast, our patient’s commencement on
quetiapine treatment, while her SSRI medication was
maintained, was related to a reduction in her CRP levels
and a clinical improvement in all other areas.
Figure 1 Development of Arthritis Pain, Depressed Mood and Level of Activity over time. The graph describes the course of levels of
arthritis pain, depressive symptoms and physical activity over an extended period between Nov. 2003 and Oct. 2008 depending on DMARD and
psychotropic medication. The psychiatric intervention in Oct. 2007 through the mood disorder clinic and the subsequent change in DMARD and
psychotropic medication indicates a significant change in symptom presentation with a decline in pain and depressive symptoms while the
activity levels increased continuously.
Baune and Eyre Journal of Medical Case Reports 2010, 4:6
http://www.jmedicalcasereports.com/content/4/1/6
Page 3 of 4Since no reports on the possible anti-inflammatory
effects, including effects on CRP levels, of quetiapine
have been published, our findings indicate that the anti-
psychotic drug quetiapine may have exerted such anti-
inflammatory effects. In addition, the sleep-inducing
properties of quetiapine might have contributed to a
symptom relief through the link between sleep improve-
ment and pain relief. All together, our patient’sc o m -
mencement on the antipsychotic medication quetiapine
is possibly responsible for the significant clinical
improvement in her physical and mental symptoms and
for the decline in her CRP levels.
Conclusions
This case report suggests that in addition to the known
anti-inflammatory effects of SSRI, the treatment particu-
larly with quetipiane may have stronger anti-inflamma-
tory (reduction of CRP levels) effects in arthritis and
comorbid major depression, which yielded a clinical
improvement of pain, depression and general function.
Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompany-
ing images. A copy of the written consent is available
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